Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer
Toripalimab Treatment Linked to Heart and Muscle Inflammation
This case report and literature review describes a 74-year-old male with stage IIIA lung squamous cell carcinoma who developed multiple immu…
A single case study shows a patient with lung cancer developed heart and muscle inflammation after receiving toripalimab treatment.
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse
Long Survival in Pancreatic Cancer Can Bring Brain Spread
This case report describes a 51-year-old man with metastatic pancreatic ductal adenocarcinoma who survived 30 months from diagnosis and 3.5 …
A single case shows pancreatic cancer that responds to treatment may later reach the brain, even after 30 months.
Toripalimab shows biochemical and radiographic response in a patient with MSI-H mCRPC
Toripalimab shows promise for a patient with advanced prostate cancer
This case report describes a 79-year-old male with MSI-H/TMB-H metastatic castration-resistant prostate cancer treated with toripalimab and …
A 79-year-old man with advanced prostate cancer saw significant tumor shrinkage and improved lab results after receiving toripalimab treatme…
PD-1/PD-L1 inhibitors with anti-angiogenic drugs achieve 48% ORR in recurrent or metastatic nasopharyngeal carcinoma
New drug combinations show promise for advanced nasopharyngeal cancer
This meta-analysis of 10 independent cohorts from 9 studies evaluates PD-1/PD-L1 inhibitors combined with small-molecule anti-angiogenic dru…
Combining certain immunotherapy drugs with anti-angiogenic agents shows a 48% response rate for patients with advanced nasopharyngeal cancer…
Toripalimab plus paclitaxel and cisplatin improves overall survival in advanced esophageal squamous-cell carcinoma
Trial shows toripalimab improves survival for advanced esophageal cancer
This Phase 3 randomized controlled trial of 514 treatment-naïve patients with advanced esophageal squamous-cell carcinoma found that toripal…
A new combination therapy involving toripalimab and chemotherapy significantly extended survival for patients with advanced esophageal squam…
Comparative Efficacy of Immunotherapy Combinations in Advanced Renal Cell Carcinoma Management
New analysis compares immunotherapy combinations for advanced renal cell carcinoma
A network meta-analysis evaluates diverse immunotherapy combinations for advanced renal cell carcinoma, highlighting specific survival benef…
A large review of over 6,000 patients identifies specific immunotherapy combinations that may improve survival for those with advanced kidne…
PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
Different PD-1 Inhibitors Show Varying Results for Nasopharyngeal Cancer
This systematic review and meta-analysis of 1,459 patients with recurrent or metastatic nasopharyngeal carcinoma found a pooled objective re…
A review of 1,459 patients shows that different PD-1 inhibitors combined with chemotherapy offer varying survival and response rates for nas…
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
New standards of care established for bladder, kidney, prostate, testicular, and penile cancers in 2025
A systematic review and meta-analysis of 40 phase II/III RCTs in patients with bladder, kidney, prostate, testicular, and penile cancers fou…
New 2025 standards of care for bladder, kidney, prostate, testicular, and penile cancers now emphasize biomarker-driven strategies and immun…